


Patent Application  
Atty. Docket No. 25302A

**IN THE CLAIMS**

Claims 1-14 (canceled).

15. (new) A compound of the formula (I):



(I)

wherein,

$\text{R}^1$  represents hydrogen or halogen;

$\text{R}^2$  represents hydrogen, 1 to 6 carbon alkyl, aminocarbonyl, or 1 to 6 carbon mono- or di-alkylaminocarbonyl;

$\text{R}^3$  represents 1 to 10 carbon alkyl substituted by 1 to 4 substituents independently selected from: hydroxy, oxo, aminocarbonyl, 1 to 6 carbon mono- or di-alkylaminocarbonyl, 1 to 6 carbon alkylsulfonylamino, 3 to 8 carbon cycloalkyl, 6 to 10 carbon aryl which may be substituted by one or more 1 to 6 carbon alkyl groups, or 5 to 10 membered heterocyclic or heterocycliccarbonyl containing 1 to 4; and

wherein the compound may be in the form of a free base, a pharmaceutically acceptable salt, solvate, or hydrate.

16. (new) The compound of claim 15, wherein  $\text{R}^1$  represents hydrogen or chlorine.

17. (new) The compound of claim 16, wherein  $\text{R}^2$  represents 1 to 6 carbon alkyl, aminocarbonyl, or 1 to 6 carbon mono- or di-alkylaminocarbonyl.

18. (new) The compound of claim 16, wherein  $\text{R}^2$  represents 1 to 6 carbon alkyl.

19. (new) The compound of claim 16, wherein  $\text{R}^2$  represents methyl or ethyl.

20. (new) The compound of claim 15, wherein  $\text{R}^1$  represents chlorine.

21. (new) The compound of claim 20, wherein  $\text{R}^2$  represents 1 to 6 carbon alkyl, aminocarbonyl, or 1 to 6 carbon mono- or di-alkylaminocarbonyl.

Patent Application  
Atty. Docket No. 25302A

22. (new) The compound of claim 20, wherein R<sup>2</sup> represents 1 to 6 carbon alkyl.

23. (new) The compound of claim 20, wherein R<sup>2</sup> represents methyl or ethyl.

24. (new) The compound of claim 15, wherein R<sup>2</sup> represents 1 to 6 carbon alkyl, aminocarbonyl, or 1 to 6 carbon mono- or di-alkylaminocarbonyl.

25. (new) The compound of claim 15, wherein R<sup>2</sup> represents 1 to 6 carbon alkyl.

26. (new) The compound of claim 15, wherein R<sup>2</sup> represents methyl or ethyl.

27. (new) The compound of any one of claims 15-17, or 24, wherein:

R<sup>3</sup> represents 1 to 8 carbon alkyl substituted by 1 to 4 substituents independently selected from: hydroxy, oxo, aminocarbonyl, 1 to 6 carbon mono- or di-alkylaminocarbonyl, 1 to 6 carbon alkylsulfonylamino, 3 to 8 carbon cycloalkyl, 6 to 10 carbon aryl which may be substituted by one or more 1 to 6 carbon alkyl groups, or 5 to 7 membered heterocyclic or heterocycliccarbonyl containing 1 to 3 heteroatoms.

28. (new) The compound of any one of claims 15-17, or 24, wherein:

R<sup>3</sup> represents 1 to 10 carbon alkyl substituted by 1 to 4 substituents independently selected from: hydroxy, oxo, 1 to 6 carbon alkylsulfonylamino, 6 to 10 carbon aryl which may be substituted by one or more 1 to 6 carbon alkyl groups, or 5 to 7 membered heterocyclic or heterocycliccarbonyl containing 1 to 3 heteroatoms.

29. (new) The compound of claim 15, wherein:

R<sup>3</sup> represents 1 to 10 carbon alkyl substituted by piperidinonyl or morpholinonyl.

30. (new) A compound selected from:

5-amino-6-chloro-N-[(1-(3,3-dimethyl-2-oxobutyl)piperidin-4-yl)methyl]-2-methylimidazo[1,2-a]pyridine-8-carboxamide;

5-amino-6-chloro-N-[(1-(2-hydroxy-3,3-dimethylbutyl)piperidin-4-yl)methyl]-2-methylimidazo[1,2-a]pyridine-8-carboxamide;

5-amino-6-chloro-2-ethyl-N-[(1-(3-morpholin-4-yl-3-oxopropyl)piperidin-4-yl)methyl]imidazo[1,2-a]pyridine-8-carboxamide;

5-amino-6-chloro-2-ethyl-N-[(1-(2-morpholin-4-yl-2-oxoethyl)piperidin-4-

Patent Application  
Atty. Docket No. 25302A

y]methyl}imidazo[1,2-a]pyridine-8-carboxamide;  
5-amino-6-chloro-N-[1-(3,3-dimethyl-2-oxo-2-butyl)piperidin-4-yl]methyl}-2-  
ethylimidazo[1,2-a]pyridine-8-carboxamide;  
5-amino-6-chloro-2-ethyl-N-[1-(2-[(methylsulfonyl)amino]ethyl)piperidin-4-  
yl]]methyl}imidazo[1,2-a]pyridine-8-carboxamide;  
5-amino-6-chloro-2-ethyl-N-[(1-2-hydroxy-2-methylpropyl)piperidin-4-  
y]methyl}imidazo[1,2-a]pyridine-8-carboxamide;  
5-amino-6-chloro-2-ethyl-N-[(2-hydroxy-2-methylpropyl)piperidin-4-yl]methyl}-2-  
methylimidazo [1,2-a]pyridine-8-carboxamide;  
5-amino-6-chloro-2-ethyl-N-[1-(4-hydroxy-3,3-dimethyl-2-oxobutyl)piperidin-4-  
y]methyl}imidazo[1,2-a]pyridine-8-carboxamide;  
5-amino-6-chloro-2-ethyl-N-[1-(2-hydroxybutyl)piperidin-4-yl]methyl}imidazo[1,2-  
a]pyridine-8-carboxamide, half oxalate salt; or  
5-amino-6-chloro-2-ethyl-N-[1-(2-oxy-2-piperidin-1-ylethyl)piperidin-4-  
y]methyl}imidazo[1,2-a]pyridine-8-carboxamide;  
wherein the compound may be in the form of a free base, a pharmaceutically  
acceptable salt, solvate, or hydrate.

31. (new) A compound selected from:

5-amino-6-chloro-N-[1-(3,3-dimethyl-2-oxo-2-butyl)piperidin-4-yl]methyl}-2-  
ethylimidazo[1,2-a]pyridine-8-carboxamide;  
5-amino-6-chloro-2-ethyl-N-[1-(2-[(methylsulfonyl)amino]ethyl)piperidin-4-  
yl]]methyl}imidazo[1,2-a]pyridine-8-carboxamide;  
5-amino-6-chloro-2-ethyl-N-[(1-2-hydroxy-2-methylpropyl)piperidin-4-  
y]methyl}imidazo[1,2-a]pyridine-8-carboxamide;  
5-amino-6-chloro-2-ethyl-N-[(2-hydroxy-2-methylpropyl)piperidin-4-yl]methyl}-2-  
methylimidazo [1,2-a]pyridine-8-carboxamide;  
5-amino-6-chloro-2-ethyl-N-[1-(4-hydroxy-3,3-dimethyl-2-oxobutyl)piperidin-4-  
y]methyl}imidazo[1,2-a]pyridine-8-carboxamide;  
5-amino-6-chloro-2-ethyl-N-[1-(2-hydroxybutyl)piperidin-4-yl]methyl}imidazo[1,2-  
a]pyridine-8-carboxamide, half oxalate salt; or  
5-amino-6-chloro-2-ethyl-N-[1-(2-oxy-2-piperidin-1-ylethyl)piperidin-4-  
y]methyl}imidazo[1,2-a]pyridine-8-carboxamide;  
wherein the compound may be in the form of a free base, a pharmaceutically  
acceptable salt, solvate, or hydrate.

Patent Application  
Atty. Docket No. 25302A

32. (new) The compound of any one of claims 15, 30, or 31, which is formulated as a pharmaceutical composition alone or in combination with at least one pharmaceutically acceptable carrier.

33. (new) The compound of claim 27, which is formulated as a pharmaceutical composition alone or in combination with at least one pharmaceutically acceptable carrier.

34. (new) A method of agonizing 5-HT<sub>4</sub> receptors comprising administering to a mammalian subject the compound of claim 15, alone or in combination with at least one pharmaceutically acceptable carrier.

35. (new) A method of antagonizing 5-HT<sub>4</sub> receptors comprising administering to a mammalian subject the compound of claim 15, alone or in combination with at least one pharmaceutically acceptable carrier.